The Downtick

GLP-1 prices, tracked and verified & the business behind them.

Slide 1

The Downtick is a twice-weekly brief on the GLP-1 economy: what the world's biggest drugs cost and what they're doing to money. Verified drug prices with dates, the Lilly-Novo ad war, the generic wave, and the patent cliffs nobody's watching. We read the primary documents, court dockets, government databases, pricing frameworks, and every number we print carries its source and the day we verified it.

Sent Twice A Week Written in English Cross Promotions Sponsorships
SubscribersLock iconLock icon
Open RateLock iconLock icon
Click RateLock iconLock icon
Added OnLock iconLock icon
Travis Paivarinta

Featured Issue

Close buttonClose button

The $450 decision.

Novo Nordisk let a $450 bill go unpaid and surrendered two years of exclusivity in a $2.5 billion market. The company insists it was on purpose. Both versions are damning.

Read Past Issues Close buttonClose button

Check out The Downtick's archive of previous issues of the newsletter.

Tools

Stats

See how this newsletters subscribers and engagement have changed over time.